CEVP, Disc & Safety Assessment Parisotto Shannon M was granted 1,758 shares and covered exercise/tax liability with 471 shares, increasing direct ownership by 17% to 8,999 units (SEC Form 4)

$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Get the next $CRL alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Parisotto Shannon M

(Last) (First) (Middle)
C/O CHARLES RIVER LABORATORIES
251 BALLARDVALE STREET

(Street)
WILMINGTON MA 01887

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEVP, Disc & Safety Assessment
3. Date of Earliest Transaction (Month/Day/Year)
01/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 27,223(1) I by Karpathos Investments LLC
Common Stock 01/31/2025 A 1,758(2) A $0 9,470 D
Common Stock 01/31/2025 F 471 D $165.57 8,999 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects the exempt transfer pursuant to Rule 16a-13 of 694 shares held by the reporting person to Karpathos Investments LLC.
2. Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 27, 2022.
/s/ Shannon M. Parisotto 02/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CRL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRL

DatePrice TargetRatingAnalyst
3/21/2025$190.00 → $170.00Buy → Neutral
Goldman
3/4/2025$155.00 → $175.00Sell → Neutral
Citigroup
3/3/2025$188.00Sell → Neutral
Redburn Atlantic
1/22/2025Outperform → Mkt Perform
William Blair
1/17/2025$250.00 → $185.00Buy → Neutral
UBS
11/18/2024$164.00Hold → Underperform
CLSA
11/7/2024$205.00Underperform → Hold
CLSA
10/23/2024$167.00Underperform
CLSA
More analyst ratings

$CRL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

    First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering's in-house drug development unit Charles River Laboratories International, Inc. (NYSE:CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need. The discovery is the first using Logica®, an artificial intelligence (AI)-powered drug development solution that translates biological insights into optimized preclinical assets. "Identification of this first lead candidate provides proof-of-concept for Logica as a

    $CRL
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Charles River Laboratories to Present at Barclays Global Healthcare Conference

    Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, at 9:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services to help p

    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • Charles River Announces Agreement with Singapore General Hospital

    Charles River to provide master cell banking and NGS testing services for cord blood derived allogeneic CAR-T cells Charles River Laboratories International, Inc. (NYSE:CRL) today announced an agreement with Singapore General Hospital (SGH) to provide Current Good Manufacturing Practice (CGMP) -compliant master cell banking (MCB) and next-generation sequencing (NGS)-based services for use in cell line characterization. SGH will use cord blood to derive and manufacture allogeneic chimeric antigen receptor (CAR) T-cells which will be used to treat patients with cancer. "We are thrilled to leverage our cell line characterization services and comprehensive NGS testing approach to support SG

    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$CRL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CRL
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CRL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CRL
SEC Filings

See more

$CRL
Leadership Updates

Live Leadership Updates

See more
  • Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

    Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow

    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

    Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated

    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

    Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology researchCharles River to make an equity investment in Aitia as part of the agreementWILMINGTON, Mass. and SOMERVILLE, Mass., Nov. 13, 2023 /PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE:CRL) and Aitia, a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™, Charles River's Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.

    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$CRL
Financials

Live finance-specific insights

See more
  • Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

    – Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP Earnings per Share of $2.66 – – Full-Year GAAP Earnings per Share of $0.20 and Non-GAAP Earnings per Share of $10.32 – – Provides 2025 Guidance – – Company Plans Stock Repurchases of Approximately $350 Million in 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023. The impact of foreign currency translation reduced report

    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call

    Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2024 financial results and provide 2025 guidance on Wednesday, February 19th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 19th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi

    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • Charles River Laboratories Announces Third-Quarter 2024 Results

    – Third-Quarter Revenue of $1.01 Billion – – Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 – – Updates 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.4%, and an acquisition contributed 0.9% to consolidated third-quarter revenue. A divestiture of a small Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, revenue declined 2.7% on an organ

    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$CRL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more